Humphries R G, Tomlinson W, O'Connor S E, Leff P
Department of Pharmacology, Fisons plc-Pharmaceutical Division, Leicestershire, England.
J Cardiovasc Pharmacol. 1990 Aug;16(2):292-7. doi: 10.1097/00005344-199008000-00016.
We examined the effect of substance P, a potent stimulator of endothelium-derived relaxing factor (EDRF) release, on responses to collagen and adenosine 3',5'-diphosphate (ADP) in an in vivo model of platelet aggregation. Substance P inhibited platelet aggregation induced in vivo by both collagen and ADP. This anti-platelet effect was particularly pronounced against collagen-induced aggregation and was prevented by prior administration of haemoglobin (Hb), a known inhibitor of EDRF-mediated responses. Collagen-induced platelet aggregation in vitro was unaffected by a concentration of substance P equivalent to that achieved in plasma following in vivo administration. This study provides a clear demonstration of the anti-platelet activity of EDRF in vivo and an indication that its effectiveness may depend on the aggregating agent used.
我们在血小板聚集的体内模型中，研究了P物质（一种内皮源性舒张因子（EDRF）释放的强效刺激剂）对胶原蛋白和3',5'-二磷酸腺苷（ADP）反应的影响。P物质抑制胶原蛋白和ADP在体内诱导的血小板聚集。这种抗血小板作用对胶原蛋白诱导的聚集尤为明显，并且可被预先给予血红蛋白（Hb，一种已知的EDRF介导反应的抑制剂）所阻断。体外胶原蛋白诱导的血小板聚集不受体内给药后血浆中所达到的P物质浓度的影响。本研究清楚地证明了EDRF在体内的抗血小板活性，并表明其有效性可能取决于所使用的聚集剂。
